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Simple Integer Risk Score to Determine Prognosis of Patients With
Hypertension and Chronic Stable Coronary Artery Disease
Anthony A. Bavry, MD, MPH; Dharam J. Kumbhani, MD, SM, MRCP; Yan Gong, PhD; Eileen M. Handberg, PhD;
Rhonda M. Cooper-DeHoff, PharmD, MS; Carl J. Pepine, MD
Background-—It is difﬁcult to accurately determine prognosis of patients with hypertension and chronic stable coronary artery
disease (CAD). Our aim was to construct a risk score for predicting important adverse events in this population.
Methods and Results-—Patients with hypertension and chronic stable CAD enrolled in the INternational VErapamil-SR/Trandolapril
STudy (INVEST) comprised the study cohort. Candidate predictor variables were obtained from patients with at least 1 postbaseline
visit. Patients were divided into development (n=18 484) and validation cohorts (n=2054). Cox regression model identiﬁed
predictors of the primary outcome: all-cause mortality, myocardial infarction, or stroke at a mean follow-up of 2.3 years. The
hazard ratio of each variable was rounded to the nearest integer to construct score weights. A score 0 to 4 deﬁned low-risk, 5 to 6
intermediate-risk and ≥7 high-risk. The following variables were retained in the ﬁnal model: age, residence, body mass index,
on-treatment heart rate and BP, prior myocardial infarction, heart failure, stroke/transient ischemic attack, smoking, diabetes,
peripheral arterial disease, and chronic kidney disease. The primary outcome occurred in 2.9% of the low-risk group, 6.5% of the
intermediate-risk group, and 18.0% of the high-risk group (P for trend <0.0001). The model was good at discriminating those who
had an event versus those who did not (C-statistic=0.75). The model performed well in a validation cohort (C-statistic=0.77).
Conclusion-—Readily available clinical variables can rapidly stratify patients with hypertension and chronic stable CAD into useful
risk categories. ( J Am Heart Assoc. 2013;2:e000205 doi: 10.1161/JAHA.113.000205)
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O ne mechanism to improve the quality and cost of healthcare delivery is to categorize patients into risk catego-
ries whereby the level of care would be targeted to the risk
proﬁle of a particular patient.1 For coronary artery disease
(CAD), expensive medications and procedures are commonly
used; however, relatively little attention has been devoted to
targeting such therapies to the overall risk of the patient.
During a patient’s lifetime, a signiﬁcant proportion of health
care delivery will take place on an outpatient level. CAD
patients are often considered “high-risk” by limited charac-
teristics such as diabetes status, but this may not provide an
accurate determination of the patient’s overall risk proﬁle and
response to certain treatments.2 Therefore, a simple means to
risk stratify chronic stable CAD patients with readily available
clinical information is needed.
A risk score (clinical decision rule) aggregates various
patient characteristics into a numerical score that can be
useful in estimating prognosis.3–6 Numerous risk scores have
been developed to risk stratify patients at the time of an
acute coronary syndrome.7–10 Unfortunately, these decision
rules do not apply to the larger group of ambulatory patients
with chronic stable CAD. Therefore, our objective was to
construct and internally validate a simple-to-use risk score
using readily available clinical data to predict future adverse
events among patients with hypertension and chronic stable
CAD.
Methods
Study Protocol
Details regarding the INternational VErapamil-SR/Trandolapril
STudy (INVEST) protocol and outcomes have been published
elsewhere.11,12 Brieﬂy, INVEST was an international random-
ized trial that compared the effects of a calcium antagonist
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(verapamil SR)-based strategy with a b-blocker (ateno-
lol)-based strategy for treatment of hypertension among
22 576 patients ≥50 years of age with clinically stable CAD.
Since there was no difference between treatment strategies,
the entire INVEST cohort was considered in the construction
of this risk score.4 CAD was deﬁned as prior myocardial
infarction, abnormal coronary angiogram (≥50% stenosis of at
least 1 major epicardial vessel), concordant abnormalities on
2 different types of cardiac tests (eg, electrocardiogram,
echocardiogram, or myocardial perfusion study), or classic
angina pectoris. The following patients were excluded:
unstable angina, coronary revascularization or stroke within
the last month, myocardial infarction within the last
3 months, b-blocker use within the last 2 weeks or within
12 months of a myocardial infarction, sinus bradycardia,
sick sinus syndrome or type 2 or 3 heart block without
permanent pacemaker, Wolf-Parkinson-White, ventricular
tachycardia or other serious arrhythmias, severe heart failure
(New York Heart Association class IV), severe renal dysfunc-
tion (creatinine ≥4.0 mg/dL), hepatic dysfunction, contrain-
dication to study medication, or life expectancy <2 years.
Enrollment began September 1997 and follow-up was
completed in February 2003. The study was conducted
according to the principles of the Declaration of Helsinki.
Local institutional review boards and ethics committees
approved the protocol and written informed consent was
obtained from all subjects.
Patient characteristics were recorded by the physician
investigator at baseline (visit 1). Coronary angioplasty repre-
sented mostly percutaneous coronary intervention with
bare-metal stents. Type of arrhythmia was not recorded;
however, due to the age of participants and exclusions for
serious arrhythmias, this mostly represented atrial ﬁbrillation
and/or ﬂutter. Although peripheral vascular disease was
recorded, we preferred to report this condition with the more
contemporary term, peripheral arterial disease.13
Protocol scheduled follow-up visits occurred every
6 weeks for the ﬁrst 6 months (visits 2 to 5), then twice
per year until 2 years after the last patient was enrolled.
Blood pressure (BP) was recorded as the mean of 2 cuff BP
measurements after the patient was sitting comfortably for at
least 5 minutes. Target BP was <140/90 mm Hg, or <130/
85 mm Hg if diabetes or chronic kidney disease was
present.14 Trandolapril and hydrochlorothiazide could also
be added as necessary to achieve target BP. Titration of study
medications was mostly complete by the 6-month visit.
The primary study outcome was the ﬁrst occurrence of
all-cause mortality, nonfatal myocardial infarction, or nonfatal
stroke. Outcomes were adjudicated by a blinded events
committee by review of pertinent patient and hospital
records. Nonfatal myocardial infarction was deﬁned as
an elevation in cardiac enzymes (troponin I or T, or
creatine-kinase myocardial band isoenzyme) greater than
the upper limit of normal with ischemic symptoms and/or
ischemic electrocardiographic changes. Nonfatal stroke was
deﬁned as a sudden onset of a neurological deﬁcit that
persisted for at least 24 hours and conﬁrmed by neurological
imaging or neurology consult.
Statistical Methods: Risk Score Construction and
Validation
Patients who had at least 1 postbaseline visit were land-
marked for analysis. To reﬂect a period of stable BP, the
6-month visit was preferentially used; however, in the absence
of 6-month data, any postbaseline visit between 6 weeks and
6 months was included, with preference given to the available
visit closest to 6 months (n=20 537). Ninety percent of this
cohort was randomly selected as a development cohort, while
the remaining 10% was utilized as an internal validation
cohort.
Our goal was to select dichotomous or categorical
variables that could be readily identiﬁed during a routine
ofﬁce visit. Age was categorized as <65 years (referent), 65
to 74 years, or ≥75 years. Residence was categorized as
North America or non-North America (Europe, Mexico, or
Caribbean [referent]). On-treatment BP was categorized
as <110 mm Hg,15,16 110 to 139 mm Hg (referent), or
≥140 mm Hg.17,18 Heart rate was categorized as <85 beats per
minute (referent) or ≥85 beats per minute.19,20 Body weight
was categorized as a body mass index (BMI) <20 kg/m2, 20
to 24.9 kg/m2, 25 to 29.9 kg/m2, versus ≥30 kg/m2
(referent).21–23 Categorization was justiﬁed due to lack of
linearity of the predictor variables on the primary outcome.
The referent category was assigned so that association
between the predictor variables and the primary outcome was
positive.
A Cox regression model tested each candidate variable
predictor of the primary outcome (all-cause mortality, nonfatal
myocardial infarction, or nonfatal stroke). An initial model
forced all candidate variables into it as a full model, while more
restrictive models were formed at a 5% and 1% signiﬁcance
level using backward elimination. An additional model only
considered nonmodiﬁable variables. The b coefﬁcients and
standard errors in each multivariable Cox regression models
are presented. Hazard ratios were calculated by taking the
exponentials of the b coefﬁcients. Hazard ratios of covariates
were rounded to the nearest integer to construct score
weights. The range of possible total score weights was divided
into approximately equal groups to stratify patients into low-,
intermediate-, and high-risk tertiles. Model discrimination was
determined by calculating the C-statistic, which is the area
under the receiver operator curve.24 Model calibration was
evaluated by the Hosmer-Lemeshow goodness-of-ﬁt test
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statistic, where the expected incidence of the primary
outcome from the development cohort was compared against
the observed incidence from the validation cohort.25 Baseline
characteristics were reported as frequencies, and continuous
and categorical variables were compared with Student’s t test
and the v2 test, respectively. A P value <0.05 was considered
signiﬁcant. Analyses were performed with SAS software 9.2
(SAS Institute, Inc). No funding was obtained for the conduct of
this study.
Results
The characteristics of the development cohort (n=18 484)
and internal validation cohort (n=2054) were similar at the
time of the landmark except for arrhythmia, which was slightly
more common in the development cohort (Table 1). Mean
heart rate and BP was 71 beats per minute and 134/
78 mm Hg, respectively. From the landmark until the end of
follow-up (mean=2.3 years), 1348 (7.3%) patients died, 262
(1.4%) had a nonfatal myocardial infarction, and 231 (1.3%)
had a nonfatal stroke.
The proportion of patients correctly classiﬁed as having a
systolic BP <110 and ≥140 mm Hg during a one-time ofﬁce
visit was compared against the mean BP from the landmark to
the end of follow-up. The sensitivity and speciﬁcity of an ofﬁce
visit BP <110 mm Hg was 70% and 97%, respectively, while
the sensitivity and speciﬁcity of an ofﬁce visit BP ≥140 was
72% and 83%, respectively.
Table 2 displays the full model and more restrictive
models constructed at the 5% and 1% signiﬁcance levels.
Since the 1% signiﬁcance level was the most parsimonious
model and retained good discrimination (C-statistic=0.75),
this was the model the risk score was built upon. We
additionally explored a model where age, BMI, heart rate, and
systolic BP were considered as continuous variables; how-
ever, this had the same discrimination as the categorical
model. We also compared gender-speciﬁc models with a
gender-pooled model and found no evidence for effect
modiﬁcation by gender. Table 3 displays the score weights
assigned to each retained predictor variable. The total
possible score was 21 points; however, no patient had a
score >18. The absolute event rate for each total point score
is provided in a score sheet in Table 4. The frequency of
distribution of risk scores is displayed in Figure 1. A score of
0 to 4 deﬁned low-risk, 5 to 6 deﬁned intermediate-risk, and
≥7 deﬁned high-risk.
The incidence of adverse events was 2.9% in the low-risk
group, 6.5% in the intermediate-risk group, and 18.0% in the
high-risk group (Figure 1). The incidence of adverse events in
the validation cohort was similarly increased in a stepwise
fashion (P for trend <0.0001; C-statistic=0.77). The Hos-
mer-Lemeshow goodness-of-ﬁt test statistic was 8.03
(P=0.43). Frequencies of individual cardiovascular outcomes
are listed in Table 5.
Figure 2 displays the risk for an adverse event according to
different eligibility criteria: any prior myocardial infarction,
known coronary stenosis or ischemia on 2 different cardiac
tests, or only classic angina pectoris. The C-statistics for
these sub-groups were 0.74, 0.76, and 0.83 for the 3 groups,
respectively. The Hosmer-Lemeshow goodness-of-ﬁt test
statistics were 4.3 (P=0.83), 7.7 (P=0.46), and 7.4 (P=0.49),
respectively.
Discussion
Our study constructed and internally validated a simple-to-use
integer risk score to predict future adverse events from a
large international database of patients with hypertension and
chronic stable CAD. This allowed us to stratify patients into
low-, intermediate-, and high-risk categories. Adverse out-
comes were primarily attributable to deaths. Strength of the
current analysis is that all of the predictors are readily
available during a routine clinic visit. The risk score had good
discriminative ability in determining which patients would
suffer from an adverse event and provided similar predictive
accuracy among different study eligibility criteria (ie, prior
myocardial infarction versus only classic angina pectoris).
Such information might be useful to select high-risk patients
for closer surveillance, more aggressive risk factor modiﬁca-
tion, and performance of diagnostic/therapeutic procedures,
while being more conservative in low-risk patients; however,
these concepts would need to be prospectively tested. Model
performance was slightly improved when comparing a model
with nonmodiﬁable factors (C-statistic=0.74) to models with
modiﬁable factors (C-statistic=0.75). This could signal the
importance of weight, heart rate, and BP control among these
patients.
We analyzed patients who had at least 1 postbaseline visit,
and preferentially used the 6-month visit when titration of
antihypertensive medications was mostly complete. Accord-
ingly, these results are generalizable to ambulatory patients
with chronic stable CAD who are on a stable antihypertensive
regimen. We decided to perform a landmark analysis for
several reasons. The mean BP in INVEST was signiﬁcantly
reduced after study medications were initiated. This mirrors
clinical practice where patients with hypertension will undergo
a dedicated attempt by their practitioner to reach target BP
through titration of antihypertensive medications. In lieu of
mean BP which would not be readily available in clinical
practice, we used a carefully measured value during 1 ofﬁce
visit. This correlated well with mean BP and had good or very
good speciﬁcity. Patients who have a one-time BP value within
the referent range (110 to 139 mm Hg), but close to the
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Table 1. Patient Characteristics at the Time of the Landmark
Characteristic Development Cohort, n=18 484 Validation Cohort, n=2054 P Value
Age, y, mean (SD) 66.0 (9.7) 66.1 (9.8) 0.76
<65 years, % 45.8 45.5 —
65 to 74 years, % 33.1 33.1 —
≥75 years, % 21.1 21.5 —
Women, % 52.1 51.1 0.38
Nonwhite race, % 48.5 49.0 0.67
Global region:
North America 77.0 79.8 0.09*
European 6.8 5.9 —
Mexico/Caribbean 16.0 14.2 —
BMI, kg/m2, mean (SD) 29.2 (6.8) 29.4 (10.4) 0.35
<20 kg/m2, % 2.2 2.4 —
20 to 24.9 kg/m2, % 19.8 19.6 —
25 to 29.9 kg/m2, % 40.2 39.4 —
≥30 kg/m2, % 37.9 38.6 —
HR, beats/minute, mean (SD) 71.3 (9.5) 71.4 (9.5) 0.48
≥85 beats/minute, % 7.1 7.3 —
SBP, mm Hg, mean (SD) 134.4 (17.2) 134.1 (17.3) 0.54
SBP <110 mm Hg, % 3.0 3.3 —
SBP ≥140 mm Hg, % 32.2 31.1 —
DBP, mm Hg, mean (SD) 78.4 (9.6) 78.3 (9.8) 0.60
History of, %
Myocardial infarction 32.2 32.3 0.89
Unstable angina 11.5 11.0 0.48
Classic angina pectoris 68.0 67.2 0.45
Coronary revascularization† 27.3 27.4 0.96
Heart failure (class I to III) 5.7 5.4 0.55
Arrhythmia‡ 7.2 5.9 0.03
Stroke/transient ischemic attack 7.6 7.1 0.41
Smoking§ 46.5 46.1 0.73
Diabetes mellitusk 29.9 30.5 0.53
Hyperlipidemia¶ 56.2 55.8 0.70
Peripheral arterial disease 12.0 11.5 0.59
Chronic kidney disease 1.9 1.8 0.64
Medications, %
Aspirin 58.1 56.0 0.06
NSAID 16.8 17.0 0.75
Lipid lowering agent 37.5 36.2 0.27
Nitrate 32.5 31.0 0.15
BMI indicates body mass index; DBP, diastolic blood pressure; HR, heart rate; kg, kilogram; m, meter; NSAID, non-steroidal anti-inﬂammatory drug; SBP, systolic blood pressure; SD,
standard deviation.
*P value across categories.
†Includes coronary artery bypass grafting and percutaneous coronary intervention.
‡Type of arrhythmia not recorded, but mostly represented atrial ﬁbrillation.
§Includes current and past smoking.
kDeﬁned as diagnosis of diabetes or use of oral hypoglycemic medications and/or insulin.
¶Deﬁned as diagnosis of hypercholesterolemia or use of lipid lowering medications.
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lower/upper threshold may need additional BP readings or
even ambulatory BP monitoring to accurately classify them.
Most of the predictors in this risk score have been well
documented to increase the hazard for adverse events:
advanced age,22,26 elevated BP,26 congestive heart fail-
ure,22,27 stroke,26 diabetes,22,26,28,29 chronic kidney dis-
ease,26,28,30,31 myocardial infarction,22,26,28 smoking,22,26
and peripheral arterial disease.13,32 However, the aggregated
effect of multiple risk factors among chronic stable CAD
patient is less well known.26,33
Accumulating evidence is challenging the paradigm that
very low BP is superior to a less stringent target for high-risk
patients. The ACCORD BP (Action to Control Cardiovascular
Risk in Diabetes—Blood–Pressure-lowering arm) trial ran-
domized diabetic patients to a goal systolic BP <120 mm Hg
(mean 119 mm Hg) compared with a goal <140 mm Hg
(134 mm Hg).34 At 4.7 years of follow-up, cardiovascular
outcomes were similar in the 2 groups. An observational study
conducted among diabetic patients with hypertension and
stable CAD, documented similar outcomes with an achieved
Table 2. Predictors of All-Cause Mortality, Non-Fatal Myocardial Infarction, or Non-Fatal Stroke
Predictor Full Model Non-Modiﬁable Factors 5% Signiﬁcance Model 1% Signiﬁcance Model
65 to 74 years of age 0.44 (0.06)* 0.47 (0.06)* 0.45 (0.06)* 0.44 (0.06)*
≥75 years of age 0.99 (0.06) 1.08 (0.06) 1.0 (0.06) 1.0 (0.06)
Male gender 0.11 (0.05) 0.08 (0.05) 0.13 (0.05)
North American residence 0.56 (0.08) 0.56 (0.08) 0.55 (0.08) 0.55 (0.08)
Nonwhite race 0.02 (0.05) 0.03 (0.05)
BMI <20 kg/m2 0.89 (0.12) 0.89 (0.12) 0.86 (0.12)
BMI 20 to 24.9 kg/m2 0.37 (0.07) 0.37 (0.07) 0.37 (0.07)
BMI 25 to 29.9 kg/m2 0.13 (0.06) 0.13 (0.06) 0.14 (0.06)
Heart rate ≥85 beats/minute 0.26 (0.08) 0.25 (0.08) 0.24 (0.08)
SBP <110 mm Hg 0.43 (0.12) 0.43 (0.12) 0.43 (0.12)
SBP ≥140 mm Hg 0.11 (0.05) 0.11 (0.05) 0.10 (0.05)
History of:
Myocardial infarction 0.35 (0.05) 0.36 (0.05) 0.38 (0.05) 0.39 (0.05)
Unstable angina 0.04 (0.07) 0.04 (0.07)
Classic angina pectoris 0.06 (0.05) 0.06 (0.05)
Coronary revascularization 0.06 (0.06) 0.05 (0.06)
Heart failure 0.62 (0.07) 0.66 (0.07) 0.66 (0.07) 0.65 (0.07)
Arrhythmia 0.10 (0.08) 0.11 (0.08)
Stroke/TIA 0.56 (0.07) 0.57 (0.07) 0.55 (0.07) 0.55 (0.06)
Smoking 0.31 (0.05) 0.33 (0.05) 0.32 (0.05) 0.35 (0.05)
Diabetes mellitus 0.54 (0.05) 0.49 (0.05) 0.55 (0.05) 0.55 (0.05)
Peripheral arterial disease 0.17 (0.06) 0.17 (0.06) 0.18 (0.06) 0.18 (0.06)
Chronic kidney disease 0.45 (0.11) 0.46 (0.11) 0.46 (0.11) 0.48 (0.11)
Left ventricular hypertrophy 0.08 (0.06) 0.07 (0.06)
Medication use:
Calcium channel-blocker strategy 0.05 (0.04)
Aspirin 0.005 (0.05)
Lipid lowering therapy 0.05 (0.06)
C-statistic 0.75 0.74 0.75 0.75
Referent age is <65 years, referent BMI is ≥30 kg/m2, referent heart rate is <85 beats/minute, and referent SBP is 110 to 139 mm Hg. BMI indicates body mass index; CI, conﬁdence
interval; kg, kilogram; m, meter; SBP, systolic blood pressure; TIA, transient ischemic attack.
*Estimated b coefﬁcients (standard error) for 4 Cox regression models adjusting for all the other variables in the model. The hazard ratios can be calculated by taking the exponential of the
b coefﬁcients.
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systolic BP <130 mm Hg compared with 130 to
<140 mm Hg.16 More concerning was the group of patients
who achieved a systolic BP <110 mm Hg in which case
all-cause mortality was increased. Lastly, a post-hoc analysis
from an acute coronary syndrome trial in which half of the
patients had hypertension, documented increased adverse
Table 3. Score Weights Assigned to Predictor Variables in the Development of the INVEST Risk Score
Characteristic
Univariate Model Multivariate Model
Score WeightHR (95% CI) P Value HR (95% CI) P Value
65 to 74 years of age 1.73 (1.53 to 1.95) <0.0001 1.56 (1.38 to 1.76) <0.0001 2
≥75 years of age 3.31 (2.95 to 3.72) <0.0001 2.71 (2.39 to 3.07) <0.0001 3
Male gender 1.22 (1.11 to 1.33) <0.0001
North American residence 1.97 (1.69 to 2.29) <0.0001 1.73 (1.48 to 2.03) <0.0001 2
Nonwhite race 0.77 (0.70 to 0.85) <0.0001
BMI <20 kg/m2 3.07 (2.46 to 3.84) <0.0001 2.38 (1.89 to 2.98) <0.0001 2
BMI 20 to 24.9 kg/m2 1.64 (1.44 to 1.85) <0.0001 1.46 (1.28 to 1.66) <0.0001 1
BMI 25 to 29.9 kg/m2 1.21 (1.08 to 1.35) 0.001 1.15 (1.02 to 1.29) 0.019 1
Heart rate ≥85 beats/minute 1.40 (1.19 to 1.63) <0.0001 1.27 (1.09 to 1.49) 0.0046 1
SBP <110 mm Hg 1.80 (1.44 to 2.25) <0.0001 1.54 (1.22 to 1.93) 0.0001 2
SBP ≥140 mm Hg 1.28 (1.16 to 1.41) <0.0001 1.11 (1.00 to 1.22) 0.043 1
History of:
Myocardial infarction 1.73 (1.58 to 1.90) <0.0001 1.48 (1.35 to 1.63) <0.0001 1
Unstable angina 1.08 (0.94 to 1.24) 0.27
Classic angina pectoris 0.71 (0.65 to 0.78) <0.0001
Coronary revascularization 1.42 (1.29 to 1.56) <0.0001
Heart failure 2.79 (2.44 to 3.20) <0.0001 1.92 (1.66 to 2.20) <0.0001 2
Arrhythmia 1.57 (1.35 to 1.82) <0.0001
Stroke/TIA 2.59 (2.29 to 2.93) <0.0001 1.74 (1.53 to 1.97) <0.0001 2
Smoking 1.42 (1.30 to 1.56) <0.0001 1.42 (1.29 to 1.57) <0.0001 1
Diabetes mellitus 1.77 (1.61 to 1.94) <0.0001 1.73 (1.57 to 1.90) <0.0001 2
Peripheral arterial disease 1.79 (1.59 to 2.01) <0.0001 1.20 (1.06 to 1.36) 0.0037 1
Chronic kidney disease 2.94 (2.38 to 3.62) <0.0001 1.62 (1.30 to 2.01) <0.0001 2
Left ventricular hypertrophy 1.22 (1.10 to 1.37) 0.0003
Medication use:
Calcium channel-blocker strategy 0.97 (0.88 to 1.06) 0.45
Aspirin 1.18 (1.07 to 1.30) 0.0008
Lipid lowering therapy 0.97 (0.87 to 1.06) 0.49
Total possible score 21
Referent age is <65 years, referent BMI is ≥30 kg/m2, referent heart rate is <85 beats/minute, and referent SBP is 110 to 139 mm Hg. BMI indicates body mass index; CI, conﬁdence
interval; kg, kilogram; HR, hazard ratio; m, meter; PAD, peripheral arterial disease; SBP, systolic blood pressure; TIA, transient ischemic attack.
Table 4. Score Sheet for Each Total Point Score
Risk Group Low Intermediate High
Total point score 0 1 2 3 4 5 6 7 8 9 10 11 ≥12
Primary outcome, % 0.7 1 2 3 4 5 8 12 16 20 25 30 ≥36
Primary outcome estimates were derived from the development cohort. Note, the score sheet was truncated at a score of 12 since risk estimation becomes somewhat unstable beyond
that point.
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events among the group with mean systolic BP
<110 mm Hg.15 Writing committees might need to consider
an optimal BP range, rather than advocating a “lower is
better” approach. Current secondary prevention guidelines
recommend treating BP to a target <140/90 mm Hg or even
lower among patients with CAD.18,35
In otherwise healthy individuals (ie, no end-organ disease),
obesity signiﬁcantly shortens one’s lifespan.36 Above a BMI of
25 kg/m2, every 5 kg/m2 increase in BMI is associated with
a 30% increase in mortality.36 However, once CAD (or other
end-organ disease) is established, the association between
obesity and adverse outcomes becomes complex.37 This
obesity paradox has been well-described and is supported by
the current study.21–23 The mechanism for this paradox is
unknown; however, central obesity (ie, waist-to-hip ratio or
waist circumference) appears to better predict adverse
outcomes than BMI.38,39 Unfortunately, measurements of
central obesity were not obtained in INVEST.
Limitations
Patients enrolled in a clinical study can be highly motivated
and might differ from the general population with CAD.
Another limitation, which is due to the study period, is that
study participants may not represent contemporary practice.
For example, drug-eluting stents were not used during
percutaneous coronary intervention and lipid lowering therapy
mostly predated the use of high-dose statin therapy.40
Aspirin use was expected to reduce adverse out-
comes22,33,41; however, this was not the case in our analysis.
Studies support the notion that CAD patients treated with
aspirin are higher-risk than CAD patients not treated with
aspirin, thus resulting in confounding by indication.42 Chronic
kidney disease, hyperlipidemia, and heart failure were based
on physician diagnosis and patient medical records. Had
serum creatinine, estimated glomerular ﬁltration rate, lipid
proﬁle, and left ventricular ejection fraction been available,
the prevalence of these conditions might have been
expanded, which could have altered the risk model. Lastly,
there were relatively few adverse events attributable to
nonfatal myocardial infarction or stroke. Although the reason
for this is unknown, the ACCORD trial similarly had a low
Figure 1. A, Frequency of risk scores from the development
cohort. Brackets indicate proportion of patients in low-risk (0 to 4),
intermediate-risk (5 to 6), and high-risk groups (≥7). B, Frequency of
the primary outcome at a mean of 2.3 years according to risk
groups. P for trend <0.0001 for both the development (C-statisit-
ic=0.75) and validation cohorts (C-statisitic=0.77).
Table 5. Incidence of Individual Cardiovascular Outcomes
Incidence, %
Low-Risk Group Intermediate-Risk Group High-Risk Group
Development Validation Development Validation Development Validation
All-cause mortality* 1.9 1.5 4.8 4.0 14.2 15.1
CV mortality 1.0 1.1 2.4 1.6 6.6 8.2
Non-CV mortality 0.5 0.6 1.9 2.1 5.9 5.9
Nonfatal MI 0.8 0.2 1.1 0.7 2.3 2.4
Nonfatal stroke 0.3 0.2 0.9 1.8 2.4 3.1
CV indicates cardiovascular; MI, myocardial infarction.
*A small percentage of mortality was adjudicated as “death conﬁrmation” only, and was not included either in CV mortality or non-CV mortality.
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frequency of these events despite enrolling high-risk diabetic
patients.43
Conclusions
In conclusion, readily available clinical variables can be
aggregated into a simple-to-use integer risk score to quan-
titate the risk of future adverse events among patients with
treated hypertension and chronic stable CAD. This risk score
can be used to stratify CAD patients into low-, intermediate-,
and high-risk categories. Ultimately, this risk score could be
incorporated into the electronic medical record to assist in
health care decisions.
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